K-V Bankruptcy May Hurt FDA's Unapproved Drug Initiative

Law360, New York (August 8, 2012, 5:40 PM EDT) -- K-V Pharmaceutical Co. claims a U.S. Food and Drug Administration decision to allow cheap compounded drugs to compete with its newly approved brand-name drug drove it to bankruptcy, a move experts say may undermine a key FDA initiative to get unapproved drugs reviewed and regulated.

In its Chapter 11 bankruptcy filing Saturday, K-V blamed its financial troubles on the FDA for undermining its exclusivity on Makena, a drug meant to prevent preterm births. Makena was approved in February 2011, as part of the FDA's efforts to...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.